Deals & Capital Markets
Vir Biotechnology Surges 55% on $1.7 Billion Astellas Deal for Prostate Cancer T-Cell Engager
4d ago
You're signed outSign in or to get full access.
Leadership at Vir Biotechnology
Browse executives, board members, and key leadership.